Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

Shares of GH Research PLC (NASDAQ:GHRS) surged 90% following the announcement that its Phase 2b trial for GH001, an inhalable treatment for treatment-resistant depression (TRD), met its primary ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available ...

All subjects have now been enrolled in Island Pharmaceutical’s phase 2b arm of its ISLA-101 trial in dengue fever. ... Read ...

"Imvax secures $29m to support Phase IIb glioblastoma therapy trial" was originally created and published by Clinical Trials ...

placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available under ...

The trial confirmed linsitinib's favorable safety profile, with no QTc prolongation and manageable adverse events. Late-stage ...

Dogwood Therapeutics, Inc. announced that it will begin dosing patients in its Phase 2b clinical trial, HALT-CINP, in Q1 2025 to study Halneuron®, a novel Nav 1.7 inhibitor aimed at treating ...

GH Research PLC will host a conference call on February 3, 2025, to discuss Phase 2b trial data for GH001. GH Research PLC announced that it will hold a conference call and live webcast on ...